C-KIT Mutation
Conditions
Keywords
Acute myeloid leukemia, c-Kit mutation, MRD
Brief summary
C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as molecular MRD monitoring is still unclear. What are the differences and advantages of using c-Kit mutation as MRD in prognostic assessment compared with other MRDs (MFC or RUNX1::RUNX1T1) widely used today? Existing data suggest that patients with one positive and one negative MRD results obtained by two different techniques have a higher risk of recurrence than patients with two negative MRD results but a lower risk of recurrence than patients with two positive MRD results. Therefore, can combining multiple MRD markers, including c-Kit mutations, overcome the shortcomings of a single molecular marker as MRD monitoring? Therefore, this project intends to confirm the clinical significance of quantitative detection of c-Kit mutation as MRD in acute myeloid leukemia.
Interventions
None listed
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who meet the diagnostic criteria(WHO 2016 criteria) of AML and have c-Kit D816 mutation. And receive treatment.
Exclusion criteria
Patients with other factors which were considered unsuitable to participate in the study by the investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CIR | Within 5 years after treatment | cumulative incidence of recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | Within 5 years after treatment | Overall Survival Rate |
| RFS | Within 5 years after treatment | Relapse-free survival |
Countries
China
Outcome results
None listed